- Home
- CNFR vs APRE Comparison
CNFR vs APRE Comparison
Compare CNFR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- APRE
- Stock Information
- Founded
- CNFR 2009
- APRE 2006
- Country
- CNFR United States
- APRE United States
- Employees
- CNFR N/A
- APRE N/A
- Industry
- CNFR Property-Casualty Insurers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNFR Finance
- APRE Health Care
- Exchange
- CNFR Nasdaq
- APRE Nasdaq
- Market Cap
- CNFR 9.9M
- APRE 9.4M
- IPO Year
- CNFR 2015
- APRE 2019
- Fundamental
- Price
- CNFR $0.74
- APRE $1.55
- Analyst Decision
- CNFR
- APRE Strong Buy
- Analyst Count
- CNFR 0
- APRE 1
- Target Price
- CNFR N/A
- APRE $20.00
- AVG Volume (30 Days)
- CNFR 11.1K
- APRE 37.1K
- Earning Date
- CNFR 08-13-2025
- APRE 08-12-2025
- Dividend Yield
- CNFR N/A
- APRE N/A
- EPS Growth
- CNFR N/A
- APRE N/A
- EPS
- CNFR 2.45
- APRE N/A
- Revenue
- CNFR $52,654,000.00
- APRE $841,012.00
- Revenue This Year
- CNFR $25.91
- APRE N/A
- Revenue Next Year
- CNFR N/A
- APRE N/A
- P/E Ratio
- CNFR $0.31
- APRE N/A
- Revenue Growth
- CNFR N/A
- APRE N/A
- 52 Week Low
- CNFR $0.42
- APRE $1.41
- 52 Week High
- CNFR $1.91
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- CNFR 40.27
- APRE 42.03
- Support Level
- CNFR $0.74
- APRE $1.49
- Resistance Level
- CNFR $0.83
- APRE $1.65
- Average True Range (ATR)
- CNFR 0.05
- APRE 0.08
- MACD
- CNFR -0.01
- APRE -0.01
- Stochastic Oscillator
- CNFR 0.00
- APRE 23.08
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.